Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Promega Receives CE Mark For Maxwell 16 IVD System
Promega’s Maxwell 16 IVD System works to the specific needs of a clinical lab. Addressing the pressure to deliver quick results, especially in the process to determine organ
Promega’s Maxwell 16 IVD System works to the specific needs of a clinical lab. Addressing the pressure to deliver quick results, especially in the process to determine organ
The arrangement provides Haemonetics with exclusive access to Alba’s comprehensive catalogue of approved reagents for use in connection with the commercialization of its Arryx laser based blood typing
The EU states are Austria, Belgium, Denmark, Finland, France, Ireland, Italy, Luxembourg, Norway, Poland, Spain and the UK. Mundipharma claimed that Bendamustine is a highly effective chemotherapy agent
Sorin Group has posted net profit of EUR23.2m for the full year 2009, compared to net loss of EUR37.1m for the prior year priod. EBITDA was EUR99.4m, an
Cytokinetics claimed that CK-2017357 is a fast skeletal muscle troponin activator and is the lead drug candidate that has emerged from the company’s skeletal muscle contractility program. CK-2017357
Synergy Pharma said that SP-304 is a member of a new class of non-systemic drugs for treatment of chronic constipation (CC), irritable bowel syndrome with constipation (IBS-C) and
The asthma programme for Relovair (previously referred to as ‘Horizon’) will assess the potential benefit of the combination of inhaled corticosteroid, fluticasone furoate and long-acting beta agonist vilanterol
FDA’s warning highlights the greater risk of developing muscle injury, including rhabdomyolysis, for patients when they are prescribed and use higher doses of Zocor drug. Simvastatin is sold
Onglyza has been submitted for regulatory review in more than 50 countries and is approved in 38 countries, including the US and member states of the EU. Onglyza
The primary objective was to demonstrate that subjects receiving Nasulin would achieve a larger increase from baseline in the mean proportion of time spent with normal glucose levels